https://doi.org/10.4081/hmr.v2i5.717

Myelodysplastic syndromes

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 195
PDF: 107
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Cazzola
support@pagepress.org
The incidence of primary myelodysplastic syndromes (MDS) is about 5 per 100,000 persons per year in the general population, but it increases to 20-50 per 100,000 persons per year after 60 years of age. About 25,000 new cases are therefore expected in the Europe each year. The FAB classification has been widely used for defining the different subtypes of MDS. More recently, the World Health Organization (WHO) classification of myeloid neoplasms has proved to be a very useful tool. The WHO classification provides valuable prognostic information and may be used for clinical decision making [Malcovati et al., J Clin Oncol 2005;23:7594-603]. The International Prognostic Scoring System (IPSS)3 – based on the percentage of marrow blasts, the cytogenetic pattern, and the number and degree of cytopenias – is useful for predicting survival and the risk of leukemia. We found that dependency on transfusions has a negative effect on the likelihood of survival [Cazzola & Malcovati, N Engl J Med 2005;352:536-8]. Based on WHO subgroups, karyotype, and transfusion requirement, we defined a time-dependent prognostic scoring system (WPSS) that can be used to predict survival and leukemia progression at any time during the clinical course of the disease. More recently, we showed that bone marrow fibrosis represents an additional independent prognostic factor, as this feature identifies a distinct clinical entity characterized by high transfusion need and poor prognosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Cazzola, M. (2009). Myelodysplastic syndromes. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.717
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).